W Justin Moore
Overview
Explore the profile of W Justin Moore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shields R, Abbo L, Ackley R, Aitken S, Albrecht B, Babiker A, et al.
Lancet Infect Dis
. 2024 Dec;
PMID: 39701120
Background: Ceftolozane-tazobactam and ceftazidime-avibactam are preferred treatment options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world comparative effectiveness studies are scarce. Pharmacokinetic and pharmacodynamic differences between the agents might affect clinical...
2.
Moore W, Boutin C, Tanna S
Curr Opin Infect Dis
. 2023 Sep;
36(6):514-521.
PMID: 37773928
Purpose Of Review: Letermovir has changed the game of primary prophylaxis against cytomegalovirus (CMV) for hematopoietic stem cell transplant (HSCT) and more recently, solid organ transplant recipients. This is largely...
3.
Wu E, Osborn R, Bertram C, Moore W, Galvin S, Bolon M, et al.
Sex Transm Dis
. 2022 Dec;
50(3):172-174.
PMID: 36455293
In this case series of 20 ambulatory and hospitalized adult patients treated for monkeypox virus at a large academic medical center in Chicago, Illinois, tecovirimat use was reserved for those...
4.
Alosaimy S, Lagnf A, Hobbs A, Mubarez M, Kufel W, Morrisette T, et al.
Clin Infect Dis
. 2022 Aug;
76(3):e1444-e1455.
PMID: 35982631
Background: Vancomycin (VAN)-associated acute kidney injury (AKI) is increased when VAN is combined with certain beta-lactams (BLs) such as piperacillin-tazobactam (TZP) but has not been evaluated with ceftolozane-tazobactam (C/T). Our...
5.
Pincus N, Joshi T, Gatesy S, Al-Heeti O, Moore W, Bachta K
IDCases
. 2022 Aug;
29:e01593.
PMID: 35966277
Infections with multidrug resistant (MDR) () are a growing problem. Vancomycin resistance in enterococci has long challenged treatment, necessitating the use of linezolid or daptomycin. Subsequently, daptomycin-, linezolid-, vancomycin-resistant (DLVRE)...
6.
Cole K, Zhou A, Jones T, Moore W, Chandler E, Zafonte V, et al.
Clin Infect Dis
. 2022 May;
74(Suppl_3):e23-e33.
PMID: 35568481
Clinicians, researchers, and the public frequently turn to digital channels and social media for up-to-the-minute information on novel therapeutics and vaccines. The value of credible infectious diseases drug information is...
7.
Wu E, Kumar R, Moore W, Hall G, Vysniauskaite I, Kim K, et al.
J Gen Intern Med
. 2022 Apr;
37(10):2505-2513.
PMID: 35469360
Background: Disparities in access to anti-SARS-CoV-2 monoclonal antibodies have not been well characterized. Objective: We sought to explore the impact of race/ethnicity as a social construct on monoclonal antibody delivery....
8.
Leung E, Crass R, Jorgensen S, Raybardhan S, Langford B, Moore W, et al.
Clin Pharmacokinet
. 2021 Dec;
61(2):155-165.
PMID: 34894345
Tocilizumab is one of few treatments that have been shown to improve mortality in patients with coronavirus disease 2019 (COVID-19), but increased demand has led to relative global shortages. Recently,...
9.
Moore W, Webb A, Wang S
Am J Health Syst Pharm
. 2021 Oct;
79(5):324-326.
PMID: 34634103
No abstract available.
10.
Rhodes N, Jozefczyk C, Moore W, Yarnold P, Harkabuz K, Maxwell R, et al.
Antimicrob Agents Chemother
. 2021 Apr;
65(7):e0041721.
PMID: 33875439
Hospitalized patients with community-acquired pneumonia (CAP) are at risk of developing Clostridioides difficile infection (CDI). We developed and tested clinical decision rules for identifying CDI risk in this patient population....